Analysis Effect of Accrual Quality, Growth Opportunity and Gender Diversity on Firm Performance (Empirical Evidence from Listed Company in Indonesia Stock Exchange)
International Journal of Contemporary Accounting · 2020
DOI: 10.25105/ijca.v1i2.6128 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Contemporary Accounting, 2020. Verfasst von Imam N. Fambudi und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
The research aims to analyze the relationship of accrual quality, growth opportunity, and gender diversity to firm performance which is divided into two-equation models namely Tobin's Q and ROA with control variables firm size, firm age and leverage using multiple regression analysis methods. The sample in this study is manufacturing companies listed on the Indonesia Stock Exchange from 2015 to 2017 with a total sample of 117 companies. The results showed that accrual quality and growth opportunity had a significant positive effect on the ROA model while gender diversity had a significant negative effect on Tobin's Q.
Zitieren
APA
Fambudi, I. N., & Fitriani, D. (2020). Analysis Effect of Accrual Quality, Growth Opportunity and Gender Diversity on Firm Performance (Empirical Evidence from Listed Company in Indonesia Stock Exchange). International Journal of Contemporary Accounting. https://doi.org/10.25105/ijca.v1i2.6128
Vancouver
Fambudi IN, Fitriani D. Analysis Effect of Accrual Quality, Growth Opportunity and Gender Diversity on Firm Performance (Empirical Evidence from Listed Company in Indonesia Stock Exchange). International Journal of Contemporary Accounting. 2020. doi:10.25105/ijca.v1i2.6128
BibTeX
@article{Fambudi2020,
author = {Fambudi, Imam N. and Fitriani, Dara},
title = {Analysis Effect of Accrual Quality, Growth Opportunity and Gender Diversity on Firm Performance (Empirical Evidence from Listed Company in Indonesia Stock Exchange)},
journal = {International Journal of Contemporary Accounting},
year = {2020},
doi = {10.25105/ijca.v1i2.6128}
}
EUVIMED